{"groups":[{"description":"Patients receive trivalent influenza vaccine IM at weeks 1, 9, and 17, and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.\n\nPneumococcal 13-valent Conjugate Vaccine: Given IM\n\nTrivalent Influenza Vaccine: Given IM","id":"FG000","title":"Arm I (Trivalent Influenza Vaccine, Prevnar)"},{"description":"Patients receive trivalent influenza vaccine IM at week 1 and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.\n\nPneumococcal 13-valent Conjugate Vaccine: Given IM\n\nTrivalent Influenza Vaccine: Given IM","id":"FG001","title":"Arm II (Trivalent Influenza Vaccine, Prevnar)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"80"},{"groupId":"FG001","numSubjects":"85"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"64"},{"groupId":"FG001","numSubjects":"81"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"4"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}